Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report sent to investors on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Price Performance Akari Therapeutics stock opened at $3.60 on Monday. Akari Therapeutics has a twelve month low of $2.81 and a […]
More Stories
FCC Reviews ‘Internet of Things’ Accrediting Program Over China Security Concerns
By Lily Zhou The Federal Communications Commission (FCC) is reviewing a cybersecurity program over security concerns related to China, FCC...
Cornerstone Wealth Management LLC Sells 114 Shares of Vanguard Large-Cap ETF (NYSEARCA:VV)
Cornerstone Wealth Management LLC reduced its position in shares of Vanguard Large-Cap ETF (NYSEARCA:VV – Free Report) by 8.0% in...
QRG Capital Management Inc. Makes New $1.34 Million Investment in Expand Energy Corporation (NASDAQ:EXE)
QRG Capital Management Inc. purchased a new position in Expand Energy Corporation (NASDAQ:EXE – Free Report) during the 1st quarter,...
Kingswood Wealth Advisors LLC Has $836,000 Stake in S&P Global Inc. (NYSE:SPGI)
Kingswood Wealth Advisors LLC trimmed its holdings in shares of S&P Global Inc. (NYSE:SPGI – Free Report) by 21.7% during...
CWA Asset Management Group LLC Sells 657 Shares of CrowdStrike (NASDAQ:CRWD)
CWA Asset Management Group LLC cut its position in shares of CrowdStrike (NASDAQ:CRWD – Free Report) by 27.0% in the...
CWA Asset Management Group LLC Purchases 856 Shares of Vanguard Industrials ETF (NYSEARCA:VIS)
CWA Asset Management Group LLC grew its stake in shares of Vanguard Industrials ETF (NYSEARCA:VIS – Free Report) by 42.8%...